Veröffentlichungen
Originalarbeiten, Bücher, Buchkapitel und Übersichtsartikel von Prof. Marcus Maurer
Verwendung: Beginnen Sie mit einer Übersicht über alle Publikationen. Verwenden Sie Tag-Links, um markierte Dokumente aufzulisten oder eine ganze Kategorie aufzulisten, z.B. Original Work (Originalarbeiten), Books (Bücher), Book Chapters (Buchkapitel), Reviews (Übersichtsartikel). Wenn Sie wissen, was Sie suchen, dann geben Sie diesen Begriff in das Suchfeld ein.
Update on rupatadine in the management of allergic disorders
Filename | 90. Mullol et al., Update rupatadine managm. all. dis.,ALLERGY 2015.pdf |
Filesize | 965,24 kB |
Version | r.090 |
Date added | Juni 25, 2020 |
Downloaded | 2 times |
Category | Reviews |
Tags | Allergic rhinitis, H1-antihistamine, PAF antagonist, rupatadine, urticaria |
Authors | Mullol, J., Bousquet, J., Bachert, C., Canonica, G. W., Giménez-Arnau, A., Kowalski, M. L., Simons, F. E. R., Maurer, M., Ryan, D., and Scadding, G. |
Citation | Mullol, J., Bousquet, J., Bachert, C., Canonica, G. W., Giménez-Arnau, A., Kowalski, M. L., Simons, F. E. R., Maurer, M., Ryan, D., and Scadding, G.: Update on rupatadine in the management of allergic disorders. Allergy 2015: 70: 1-24. |
Corresponding authors | Mullol, J. |
DocNum | r.90 |
DocType | |
Edition; Page | 70: 1-24 |
IF | 6.33 |
Publisher | Allergy |
ReleaseDate | 2015 |
In a review of rupatadine published in 2008, the primary focus was on its role as an antihistamine, with a thorough evaluation of its pharmacology and inter- action with histamine H1-receptors. At the time, however, evidence was already emerging of a broader mechanism of action for rupatadine involving other mediators implicated in the inflammatory cascade. Over the past few years, the role of platelet-activating factor (PAF) as a potent mediator involved in the hypersensitivity-type allergic reaction has gained greater recognition. Rupatadine has dual affinity for histamine H1-receptors and PAF receptors. In view of the Allergic Rhinitis and its Impact on Asthma group’s call for oral antihistamines to exhibit additive anti-allergic/anti-inflammatory properties, further exploration of rupatadine’s anti-PAF effects was a logical step forward. New studies have demonstrated that rupatadine inhibits PAF effects in nasal airways and produces a greater reduction in nasal symptoms than levocetirizine. A recent meta-analysis involving more than 2500 patients has consolidated the clinical evidence for rupatadine in allergic rhinoconjunctivitis in adults and children (level of evidence Ia, recommendation A). Other recent advances include obser- vational studies of rupatadine in everyday clinical practice situations and approval of a new formulation (1 mg/ml oral solution) for use in children. In this reappraisal, we revisit some key properties and pivotal clinical studies of ru- patadine and examine new clinical data in more detail including studies that measured health-related quality of life and studies that investigated the efficacy and safety of rupatadine in other indications such as acquired cold urticaria, mosquito bite allergy and mastocytosis.
(Last update: 12.2023)
Number of original publications in peer-reviewed journals: | 580 |
Number of reviews in peer-reviewed journals: | 210 |
Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
Um die angebotenen Veröffentlichungen herunterladen zu können, müssen Sie sich einloggen. Wenn Sie das Login nicht kennen, schreiben Sie mir bitte Ihre Anfrage.